Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Author:
- 28 January 2015
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 29 (3) , 373-383
Abstract
Background: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality by suppressing HIV replication. The prognostic value of persistent low-level viremia (LLV), particularly for clinical outcomes, is unknown. Objective: Assess the association of different levels of LLV with virological failure, AIDS event, and death among HIV-infected patients receiving combination ART. Methods: We analyzed data from 18 cohorts in Europe and North America, contributing to the ART Cohort Collaboration. Eligible patients achieved viral load below 50 copies/ml within 3–9 months after ART initiation. LLV50–199 was defined as two consecutive viral loads between 50 and 199 copies/ml and LLV200–499 as two consecutive viral loads between 50 and 499 copies/ml, with at least one between 200 and 499 copies/ml. We used Cox models to estimate the association of LLV with virological failure (two consecutive viral loads at least 500 copies/ml or one viral load at least 500 copies/ml, followed by a modification of ART) and AIDS event/death. Results: Among 17 902 patients, 624 (3.5%) experienced LLV50–199 and 482 (2.7%) LLV200–499. Median follow-up was 2.3 and 3.1 years for virological and clinical outcomes, respectively. There were 1903 virological failure, 532 AIDS events and 480 deaths. LLV200–499 was strongly associated with virological failure [adjusted hazard ratio (aHR) 3.97, 95% confidence interval (CI) 3.05–5.17]. LLV50–199 was weakly associated with virological failure (aHR 1.38, 95% CI 0.96–2.00). LLV50–199 and LLV200–499 were not associated with AIDS event/death (aHR 1.19, 95% CI 0.78–1.82; and aHR 1.11, 95% CI 0.72–1.71, respectively). Conclusion: LLV200–499 was strongly associated with virological failure, but not with AIDS event/death. Our results support the US guidelines, which define virological failure as a confirmed viral load above 200 copies/ml.Keywords
This publication has 33 references indexed in Scilit:
- Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level ViremiaAntimicrobial Agents and Chemotherapy, 2012
- Episodes of HIV Viremia and the Risk of Non-AIDS Diseases in Patients on Suppressive Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-PatientsPLOS ONE, 2012
- HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variabilityBMC Infectious Diseases, 2012
- Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV?Clinical Infectious Diseases, 2012
- Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line TherapyThe Journal of Infectious Diseases, 2011
- Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremiaAIDS, 2011
- Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- The Challenge of Finding a Cure for HIV InfectionScience, 2009
- Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcomeJournal of Antimicrobial Chemotherapy, 2008